Biostimulation with polynucleotide cream during adjuvant therapy for breast cancer

To evaluate the efficacy and safety of a polynucleotide-based vaginal cream for the treatment of genitourinary syndrome of menopause (GSM) in breast cancer patients receiving adjuvant therapy.

A prospective, single-arm longitudinal study was conducted at the University of Naples Federico II. Sixty women with breast cancer and GSM were treated with a polynucleotide-based vaginal cream for 6 months according to a standardized regimen. Clinical and patient-reported outcomes were assessed at baseline, 1 month, and 6 months. Endpoints included the Vaginal Health Index (VHI), Vulvar Assessment Score (VuAS), Vaginal Assessment Score (VAS), Female Sexual Function Index-6 (FSFI-6), International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF), and global patient satisfaction.

Of the 60 women enrolled (mean age 50.6 ± 7.0 years), 53 completed the study. At 6 months, the mean VHI increased from 11.9 ± 2.3 to 17.6 ± 2.4, while the VAS and VuAS decreased from 6.3 ± 2.0 to 2.3 ± 1.1 and from 4.7 ± 2.0 to 1.4 ± 1.5, respectively (all p < 0.001). Dyspareunia, vaginal dryness, and vulvar itching were significantly improved. Mild improvements were also observed in sexual function and urinary symptoms. The treatment was well tolerated, with no serious adverse events reported.

For breast cancer survivors receiving adjuvant therapy, polynucleotide-based vaginal cream is a well-tolerated, non-hormonal option that effectively manages GSM.